Oncology

Kinetic Principles of Systemic Oncological TreatmentPharmacokinetic Fundamentals and Dosage

Nitrogen Mustards and Oxazaphosphorines: Cyclophosphamide and IfosfamideClassic Cytotoxics · DNA Modifiers

Platinum Coordinates: Cisplatin, Carboplatin and OxaliplatinHigh Density Cytotoxics · Metallodrugs

Pyrimidine Analogs: 5-Fluorouracil and CapecitabineCellular Synthetic Blockade Modulators

Folate Analogs at Oncogenic Doses: MethotrexateCompetitive Inhibition of Purines and Pyrimidines

Cytidine Analogues: Cytarabine and GemcitabineCytotoxic DNA Incorporators · Nucleosides

Anthracyclines and Intercalation Inhibitors: Doxorubicin and EpirubicinHigh Potency Intercalation Cytotoxics

Topoisomerase I and II inhibitors: Irinotecan and EtoposideInhibitors of Cell Topology and the Mitotic Cycle

Microtubule Modulators (Taxanes): Paclitaxel and DocetaxelMitosis and Cytoskeleton Inhibitors

Vinca Alkaloids: Vincristine and VinblastineInhibitors of Mitotic and Neuronal Assembly

Targeted Monoclonal Antibodies: Anti-HER2 (Trastuzumab and Pertuzumab)Targeted Immunotherapy and Epidermal Growth Inhibitors

Monoclonal Antibodies: Cetuximab (Anti-EGFR) and Bevacizumab (Anti-VEGF)Vascular Signaling and Growth Blockade Immunology

Selective Tyrosine Kinase Inhibitors: Imatinib and OsimertinibTargeted Small Molecule Therapies

Multikinase Inhibitors: Sorafenib and RegorafenibTargeted Multikinase and Antiangiogenic Therapies

Immune Checkpoint Inhibitors (Checkpoints): Pembrolizumab, Nivolumab and IpilimumabAdvanced Biological Immunomodulation and T Cell Activation

Oncological Endocrine Therapy: Tamoxifen, Anastrozole and LetrozoleEndocrine Therapeutics of Nuclear Receptor Blockade

CDK4/6 and PARP inhibitors: Palbociclib and OlaparibTherapies Directed at the Cell Cycle and DNA Repair

Advanced Clinical Support: Febrile Neutropenia and Tumor Lysis SyndromeTreatment of Oncological Complications and Emergencies

Integrated Summary of Pharmacological Adjustment and SafetyComparative Table of Clinical Settings and Safety